Cell Reprogramming for Stable Neural Stem-Like Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for reprogramming cells, particularly to create stable neural stem-like cells, face challenges such as transient phenotypical changes, reliance on artificial gene expression, and ethical concerns with fetal tissue, leading to inefficiencies and potential health risks.
Innovation Solution
A method involving transient increase of intracellular reprogramming agents like Msi1 and Ngn2 polypeptides, combined with histone acetylation and DNA demethylation inhibitors, to induce stable expression of neural stem-like cell markers in somatic cells, avoiding embryonic stem cell characteristics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If forced gene expression (e.g., c-myc) is used to change cell phenotype, then cells acquire new characteristics (e.g., neuroprogenitor characteristics), but cells become immortal and revert when forced expression is removed
Solution Approach 1:
The patent extracts and removes the forced gene expression component from the reprogramming process. Instead of relying on continuous external gene forcing, the invention uses transient expression of reprogramming factors (Oct4, Sox2, Klf4, c-Myc) followed by their removal, allowing cells to stably maintain the new phenotype without continuous artificial intervention.
Solution Approach 2:
The patent applies preliminary action by transiently expressing reprogramming factors before removing them. The factors are introduced temporarily to initiate the reprogramming process, and then removed to allow the cell to stabilize in its new state. This preliminary intervention creates lasting change without requiring continuous forcing.
2Adaptability or versatility
If retroviral gene induction is used to create stem cells, then cells acquire stem cell characteristics, but cells become cancerous and require constant artificial induction
Solution Approach 1:
The patent extracts and eliminates the retroviral integration component that causes cancerous transformation. Instead of using integrating retroviruses that permanently insert oncogenic sequences into the genome, the invention uses non-integrating methods (plasmid transfection, protein transduction) that temporarily deliver reprogramming factors without genomic integration, thereby preventing tumorigenesis.
Solution Approach 2:
The patent uses disposable, non-integrating delivery vehicles (plasmids, proteins) that perform their reprogramming function temporarily and then are degraded or removed. These short-lived reprogramming factors deliver the necessary genetic information without permanently altering the genome, avoiding the cancer risk associated with permanent viral integration.
3Adaptability or versatility
If media supplements and culture conditions are used to force phenotypical change, then cells show altered markers, but changes are transient and require constant forcing
Solution Approach 1:
The patent uses preliminary action by transiently expressing reprogramming factors to initiate stable phenotypical change. The reprogramming factors are introduced temporarily to trigger the molecular cascades that lead to stable gene expression patterns, after which the factors themselves are removed and the new phenotype is maintained without continuous intervention.
Solution Approach 2:
The patent enables self-service by creating cells that autonomously maintain their reprogrammed state through endogenous gene expression. Once the reprogramming factors initiate the transition, the cell's own regulatory networks (including stem cell maintenance genes and epigenetic mechanisms) take over to sustain the new phenotype without requiring continuous external forcing or supplements.
4Adaptability or versatility
If genome-wide DNA demethylation and histone acetylation are used to create multipotent cells, then cells show altered markers, but cells are not stable and cannot proliferate
Solution Approach 1:
The patent applies parameter changes by precisely controlling the duration, concentration, and combination of reprogramming factors. Instead of using extreme or prolonged demethylation and acetylation that lead to instability, the invention uses optimized transient expression levels of Oct4, Sox2, Klf4, and c-Myc that achieve the necessary epigenetic remodeling while maintaining genomic stability and cellular viability.
Data Source
AI summary
A method of obtaining a pluripotent-like multipotent cell, including providing a cell of a first type which is not a pluripotent-like multipotent cell; contacting the cell of a first type with an agent capable of remodeling the chromatin and/or DNA of the cell; transiently increasing expression of at least one pluripotent gene regulator in the cell of a first type, to a level at which the at least one pluripotent gene regulator is capable of driving transformation of the cell of a first type into the pluripotent-like multipotent cell; and placing or maintaining the cell in a differentiation medium and maintaining intracellular levels of the at least one pluripotent gene regulator for a sufficient period of time to allow a stable pluripotent-like multipotent cell to be obtained; wherein the pluripotent-like multipotent cell so obtained does not exhibit teratoma formation in vivo.